Literature DB >> 34341870

TUG1 knockdown suppresses cardiac fibrosis after myocardial infarction.

Qingsong Sun1, Man Luo1, Zhiwei Gao1, Xiang Han1, Zhuan Yan1, Shouxiang Xie1, Hongmei Zhao2, Hong Sun3.   

Abstract

Cardiac fibrosis is involved in myocardial remodeling following acute myocardial infarction (AMI), which can result in heart failure, arrhythmias and even sudden cardiac death. Investigating the molecular mechanisms of cardiac fibrosis in acute myocardial infarction (AMI) is essential for better understanding this pathology. The current study aims to investigate the effect of TUG1 on cardiac fibrosis after AMI and elucidated the underlying molecular mechanism of AMI. Rats were randomly divided into four groups (sham-operation group, myocardial infarction group (AMI group), si-NC treated group and si-TUG1 treated group). The biological behavior of cardiac fibroblasts treated with TGF-β1after being transfected by si-TUG1 or miR-590 mimic or miR-590 inhibitor or FGF1 mimic or a combination was evaluated using the cell counting kit-8 (CCK8) and Transwell assays. SatarBase v2.0 was used to predict the target microRNAs binding site candidates with TUG1 and FGF1. Western blot and recovery experiments were used to explore the potential mechanism. TUG1 expression was up-regulated and knockdown of TUG1 improved cardiac function in AMI rats. Knockdown of TUG1 suppressed cell viability and migration and improved collagen production of TGF-β1 treated cardiac fibroblasts. SatarBase v2.0 showed TUG1 served as a sponge for miR-590 and FGF1 is a direct target of miR-590. TUG1 expression was increased in AMI tissue and cardiac fibroblasts treated with TGF-β1. TUG1 knockdown suppressed the biological process of cardiac fibroblasts treated with TGF-β1 by sponging miR-590.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34341870     DOI: 10.1007/s00335-021-09895-z

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  2 in total

1.  LncRNA TUG1 inhibits the proliferation and fibrosis of mesangial cells in diabetic nephropathy via inhibiting the PI3K/AKT pathway.

Authors:  X-J Zang; L Li; X Du; B Yang; C-L Mei
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-09       Impact factor: 3.507

2.  MicroRNA-29b upregulation improves myocardial fibrosis and cardiac function in myocardial infarction rats through targeting SH2B3.

Authors:  Y Wang; B-J Jin; Q Chen; B-J Yan; Z-L Liu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-11       Impact factor: 3.507

  2 in total
  3 in total

Review 1.  Post-Transcriptional Regulation of Molecular Determinants during Cardiogenesis.

Authors:  Estefania Lozano-Velasco; Carlos Garcia-Padilla; Maria Del Mar Muñoz-Gallardo; Francisco Jose Martinez-Amaro; Sheila Caño-Carrillo; Juan Manuel Castillo-Casas; Cristina Sanchez-Fernandez; Amelia E Aranega; Diego Franco
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

2.  Analysis of susceptibility genes and myocardial infarction risk correlation of ischemic cardiomyopathy based on bioinformatics.

Authors:  Nai Zhang; Chuang Yang; Yu-Juan Liu; Peng Zeng; Tao Gong; Lu Tao; Xin-Ai Li
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

Review 3.  The Regulation Mechanisms and Clinical Application of MicroRNAs in Myocardial Infarction: A Review of the Recent 5 Years.

Authors:  Chan Wu; Binghong Liu; Ruiying Wang; Gang Li
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.